Find Out if You Qualify for a Financial Reward by filling out the form below.
Investigation Details
On November 4, 2022, Proto reported Q3 results meeting the low end of its prior guidance and then announced lower than expected guidance for Q4 2024. Proto attributed it to “a decline in our injection molding revenue, predominantly due to the challenging macroeconomic climate” in addition to the negative impacts of foreign currency and “the closure of [Proto’s] Japan operation.” Analysts were skeptical of Proto’s explanation, pointing to increased competition as an alternate contributing factor for the decline.
Following this news, Proto’s stock price fell by $11.09 per share to close at $24.62 per share.
Ticker Symbol | Company Name | Join Deadline | Join |
---|---|---|---|
APLT | Applied Therapeutics, Inc. | February 18, 2025 | Join |
BIOA | BioAge Labs, Inc. | March 10, 2025 | Join |
PCRX | Pacira BioSciences, Inc. | March 14, 2025 | Join |
NVO | Novo Nordisk A/S | March 25, 2025 | Join |
GO | Grocery Outlet Holding Corp. | March 31, 2025 | Join |
NEM | Newmont Corporation | April 01, 2025 | Join |
GSK | GSK plc | April 07, 2025 | Join |
NTLA | Intellia Therapeutics, Inc. | April 14, 2025 | Join |
MRK | Merck & Co., Inc. | April 14, 2025 | Join |